Artal Group S.A. Mirati Therapeutics, Inc. Transaction History

Artal Group S.A.

$214 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$27.8 - $45.35 $860,549 - $1.4 Million	-30,955 Reduced 1.51%	2,024,226 $88.2 Million
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $18.7 Million - $25.6 Million	517,472 Added 33.65%	2,055,181 $74.3 Million
Q1 2023 May 12, 2023	SELL	$36.54 - $54.26 $10.8 Million - $16 Million	-295,049 Reduced 16.1%	1,537,709 $57.2 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $21 Million - $50.1 Million	507,758 Added 38.32%	1,832,758 $83 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $13.4 Million - $19.5 Million	225,000 Added 20.45%	1,325,000 $92.5 Million
Q2 2022 Aug 11, 2022	SELL	$39.16 - $88.71 $9.79 Million - $22.2 Million	-250,000 Reduced 18.52%	1,100,000 $73.8 Million
Q1 2022 May 12, 2022	SELL	$75.82 - $150.97 $3.79 Million - $7.55 Million	-50,000 Reduced 3.57%	1,350,000 $111 Million
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $26.4 Million - $38.1 Million	200,000 Added 16.67%	1,400,000 $205 Million
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $46.2 Million - $62.1 Million	350,000 Added 41.18%	1,200,000 $212 Million
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $18 Million - $22.5 Million	125,000 Added 17.24%	850,000 $137 Million
Q1 2021 May 14, 2021	BUY	$158.92 - $221.61 $35.8 Million - $49.9 Million	225,000 Added 45.0%	725,000 $124 Million
Q3 2020 Nov 13, 2020	BUY	$113.26 - $167.27 $56.6 Million - $83.6 Million	500,000 New	500,000 $83 Million
Q4 2019 Feb 13, 2020	SELL	$70.76 - $128.86 $14.2 Million - $25.8 Million	-200,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $3.9 Million - $5.48 Million	50,000 Added 33.33%	200,000 $15.6 Million
Q2 2019 Aug 09, 2019	SELL	$59.49 - $104.71 $1.49 Million - $2.62 Million	-25,000 Reduced 14.29%	150,000 $15.5 Million
Q1 2019 May 10, 2019	BUY	$43.65 - $78.95 $7.64 Million - $13.8 Million	175,000 New	175,000 $12.8 Million
Q1 2018 May 10, 2018	SELL	$17.2 - $34.95 $1.72 Million - $3.5 Million	-100,000 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$12.65 - $19.0 $1.27 Million - $1.9 Million	100,000	100,000 $1.83 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account